At Canexia Health we want every organization to have affordable access to the latest precision oncology technology. That’s why we distribute our unique and cost-effective assay methodologies with easy-to-use software, which combines the latest in machine learning technologies with your in-house solutions.
Our white-labelled technology transfer allows your organization to provide precision oncology testing through our centralized or distributed models to ensure that your patients right now and in the future can benefit from the latest NGS methods, even if you don’t yet have an instrument.
Unlike other solutions, Canexia Health provides powerful end-to-end precision oncology solutions regardless of your organization’s size.
We’re partnering with several organizations to investigate longitudinal disease monitoring and integrate clinical data points and imaging data with genomics information. Contact us to find out more about these study opportunities.
Canexia’s proprietary bioinformatics platform provides a complete end-to-end solution, from mutation identification to auto-generated clinical reports. Our fully automated system is scalable, secure, and traceable, with a high throughput production mode that leverages the power of cloud computing.
Our platform includes:
Custom sequence pre-processing to variant annotation with built-in, rigorous, proprietary quality control (Quality Nexus™).
Store, manage, and analyze anonymized, aggregate data for assay improvement, ensuring data integrity and scalability.
Information from over 30 sources, including the FDA, EMA, NCCN, Pubmed, NCBI, NIH, clincaltrials.gov, Health Canada and others, curated and reviewed by a team of scientists and experts. Includes both single variant and combination variant interpretations.
Auto-generated clinical reports are seamlessly integrated into partners' LIMS.
All Canexia Health products come with our patented molecular and computational quality assurance platform, Quality Nexus, which enables robust mutation detection across the full range of clinical diagnostic samples collected in routine pathology workflows.
Quality Nexus also allows us to provide the highest level of quality assurance for our assays, safeguarding patients and allowing oncologists access to the information needed to identify targeted cancer treatments.
Canexia Health’s thermodynamically balanced sets of proprietary barcodes permit the best-in-class detection of low-frequency mutations. Our machine learning approach for single nucleotide variant calling allows us to infer molecular diversity indices and distinguish artifacts from true mutations.
A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.
Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.
Tailor treatment decisions based on somatic mutations in your patient’s tumor.
Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.
Contact us to learn more about our assays, informatics, or support, and learn more about becoming a Canexia partner.
This technical note describes the NGS assays developed by Canexia Health for somatic testing of adult solid tumors and how they are made available through local laboratories via our proprietary technology transfer model.